In a filing, Protagonist Therapeutics Inc revealed its Chief Medical Officer MOLINA ARTURO MD unloaded Company’s shares for reported $0.57 million on Jun 10 ’25. In the deal valued at $57.03 per share,10,000 shares were sold. As a result of this transaction, MOLINA ARTURO MD now holds 83,892 shares worth roughly $4.59 million.
Then, MOLINA ARTURO MD sold 10,000 shares, generating $555,100 in total proceeds. Upon selling the shares at $55.51, the Chief Medical Officer now owns 83,892 shares.
Before that, ARTURO MOLINA bought 10,000 shares. Protagonist Therapeutics Inc shares valued at $570,269 were divested by the Officer at a price of $57.03 per share.
Goldman initiated its Protagonist Therapeutics Inc [PTGX] rating to a Neutral in a research note published on December 06, 2024; the price target was $47. A number of analysts have revised their coverage, including BMO Capital Markets’s analysts, who began to cover the stock in early December with a ‘”an Outperform”‘ rating. Wedbush began covering PTGX with “an Outperform” recommendation on November 05, 2024. TD Cowen started covering the stock on September 24, 2024. It rated PTGX as “a Buy”.
Price Performance Review of PTGX
On Monday, Protagonist Therapeutics Inc [NASDAQ:PTGX] saw its stock fall -3.03% to $54.66. Over the last five days, the stock has lost -1.83%. Protagonist Therapeutics Inc shares have risen nearly 41.61% since the year began. Nevertheless, the stocks have risen 60.91% over the past one year. While a 52-week high of $60.60 was reached on 03/12/25, a 52-week low of $30.67 was recorded on 02/25/25.
Levels Of Support And Resistance For PTGX Stock
The 24-hour chart illustrates a support level at 53.63, which if violated will result in even more drops to 52.60. On the upside, there is a resistance level at 56.36. A further resistance level may holdings at 58.06.
The most recent change occurred on September 09, 2024 when Truist began covering the stock and recommended ‘”a Buy”‘ rating along with a $60 price target.
